Skip to main content
Journal cover image

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.

Publication ,  Journal Article
Mangia, A; Thompson, AJ; Santoro, R; Piazzolla, V; Tillmann, HL; Patel, K; Shianna, KV; Mottola, L; Petruzzellis, D; Bacca, D; Carretta, V ...
Published in: Gastroenterology
September 2010

BACKGROUND & AIMS: Polymorphisms in the region of the interleukin (IL)-28B gene on chromosome 19 have been associated with peginterferon-alfa-induced clearance of genotype 1 hepatitis C virus (HCV); there are no data for patients with genotype 2 or 3 HCV. We evaluated the effects of IL-28B polymorphisms on response to treatment with peginterferon and ribavirin in a well-characterized cohort of genotype 2/3 patients. METHODS: DNA was analyzed from 268 patients (Caucasian: genotype 2, 213; genotype 3, 55). Patients were randomly assigned to groups that received standard duration (24 wk; n = 68) or variable durations of therapy. Patients who received variable durations (VD) and had a rapid virologic response (RVR) were treated for 12 weeks (VD12; n = 122); those without an RVR were treated for 24 weeks (VD24; n = 78). IL-28B genotypes (rs12979860) were analyzed for association with treatment response. RESULTS: The frequencies of the IL-28B genotypes were as follows: CC, 37%; CT, 48%; and TT, 15%; 82% of patients with the CC genotype achieved a sustained virologic response (SVR), compared with 75% with the CT and 58% with the TT genotypes (P = .0046). Differences between IL-28B genotypes were greatest among patients who failed to attain RVR (VD24 SVR rates: CC, 87%; CT, 67%; and TT, 29%; P = .0002). Among patients with RVRs (61%), the IL-28B genotype was not associated with SVR (>70% for all IL-28B genotypes). In a multivariable logistic regression model, IL-28B genotype predicted SVR (odds ratio, 1.76; 95% confidence interval, 1.16-2.7). CONCLUSIONS: An IL-28B polymorphism was associated with an SVR in patients infected with genotype 2/3 HCV who did not achieve a RVR. Analysis of IL-28B genotype might be used to guide treatment for these patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

September 2010

Volume

139

Issue

3

Start / End Page

821 / 827.e1

Location

United States

Related Subject Headings

  • Viral Load
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Ribavirin
  • Recurrence
  • Recombinant Proteins
  • RNA, Viral
  • Prospective Studies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mangia, A., Thompson, A. J., Santoro, R., Piazzolla, V., Tillmann, H. L., Patel, K., … McHutchison, J. G. (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 139(3), 821-827.e1. https://doi.org/10.1053/j.gastro.2010.05.079
Mangia, Alessandra, Alexander J. Thompson, Rosanna Santoro, Valeria Piazzolla, Hans L. Tillmann, Keyur Patel, Kevin V. Shianna, et al. “An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.Gastroenterology 139, no. 3 (September 2010): 821-827.e1. https://doi.org/10.1053/j.gastro.2010.05.079.
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010 Sep;139(3):821-827.e1.
Mangia, Alessandra, et al. “An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.Gastroenterology, vol. 139, no. 3, Sept. 2010, pp. 821-827.e1. Pubmed, doi:10.1053/j.gastro.2010.05.079.
Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010 Sep;139(3):821-827.e1.
Journal cover image

Published In

Gastroenterology

DOI

EISSN

1528-0012

Publication Date

September 2010

Volume

139

Issue

3

Start / End Page

821 / 827.e1

Location

United States

Related Subject Headings

  • Viral Load
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Ribavirin
  • Recurrence
  • Recombinant Proteins
  • RNA, Viral
  • Prospective Studies